6500.1 Upon the issuance of a testing laboratory license, ABCA shall provide notice in the District of Columbia Register that a testing lab has become operational and that the testing requirement is in effect.

6500.2 Once notice of the issuance of a testing lab is issued in the District of Columbia Register, no medical cannabis or medical cannabis product shall be sold or distributed to an internet retailer, manufacturer, retailer, qualifying patient or caregiver until it has been tested and determined to be unadulterated as provided by this title.

6500.3 No licensee shall distribute, sell, or transfer adulterated medical cannabis to another licensee or person unless the product is being sent to a testing laboratory for the purposes of testing in compliance with the Act and this subtitle, for the purposes of disposal or destruction, complying with a court order, law enforcement investigation, or order of the Board.

6500.4 Section 6503 through 6600 shall not apply to the testing of medical cannabis samples provided by qualifying patients in accordance with the Act.

6500.5 Section 6503 through 6600 shall not apply to the testing of medical cannabis samples from cultivation centers and manufacturers for the purposes of quality assurance, research, and development in accordance with the Act so long as such samples are not dispensed, distributed, or sold to internet retailers, retailers, or the public.

SOURCE: Final Rulemaking published at 73 DCR 002136 (February 20, 2026).